Decoding HER2: A Guide to Understanding Gastric Cancer Testing and Treatment
"Navigating the Complexities of HER2 Testing in Advanced Gastric and Gastro-Oesophageal Cancer"
Gastric cancer, also known as stomach cancer, remains a significant global health concern, affecting millions of people worldwide. Its complexity lies not only in its various subtypes but also in the evolving landscape of treatment options. One critical aspect of managing this disease is understanding the role of the human epidermal growth factor receptor 2, or HER2, a protein that can influence how cancer cells grow and spread.
HER2 testing has emerged as a crucial tool in guiding treatment decisions for advanced gastric and gastro-oesophageal junction (GOJ) cancers. The presence or absence of HER2 in cancer cells helps doctors determine the most effective course of action, including targeted therapies that can significantly improve patient outcomes. This guide aims to demystify the process of HER2 testing, explain its significance, and provide insights into the latest advancements in treatment.
This article will explore the nuances of HER2 testing, the importance of accurate assessment, and the implications for patients facing a diagnosis of advanced gastric or GOJ cancer. We'll break down the testing procedures, discuss the different criteria used to determine HER2 status, and highlight the impact of these findings on treatment strategies, empowering readers to better understand their diagnosis and treatment options.
Testing Shapes Treatment
The 2025 SAPHIR registry examined local and central testing for HER2, PD-L1, MSI/MMR, EBV, and CLDN18.2 in advanced gastric cancer. GASTHER2 reported that accurate HER2 assessment is essential for treatment selection and evaluated reassessment after progression in initially HER2-negative advanced gastric cancer. Results from the NCT04704934 study also found that concordance between local and central HER2 status varied by assay type, while both primary and metastatic tissue may be suitable for testing.
A Careful Testing Process
HER2 testing in gastric cancer is generally used to help characterize the tumor and inform treatment decisions, but the exact approach can vary by clinical setting and laboratory practice. Results may require cautious interpretation because tumor biology and test performance are not always uniform. Patients should discuss the testing method, specimen used, and implications of the result with their oncology and pathology teams.
From Biomarker to Treatment Guide
HER2 testing helped establish a model in which a tumor biomarker can guide targeted treatment in gastric cancer. Over time, clinical practice has increasingly connected pathology results with treatment selection and reassessment. The field continues to evolve as researchers study differences between tumor sites and changes in HER2 status.
Unraveling HER2: What You Need to Know About Testing
HER2 testing is a sophisticated process designed to assess the levels of HER2 protein in cancer cells. This protein, when overexpressed, can drive cancer growth and make it more aggressive. The testing process involves several steps, beginning with obtaining a tissue sample, usually through an endoscopic biopsy or surgical resection. These samples are then analyzed in specialized laboratories using various techniques.
- Immunohistochemistry (IHC): This method uses antibodies to detect the presence of HER2 protein in cancer cells. The results are typically scored on a scale, with higher scores indicating greater HER2 protein levels.
- In Situ Hybridization (ISH): ISH techniques, such as dual-probe ISH, are used to determine the number of HER2 genes present in cancer cells. This helps assess if the HER2 gene is amplified, which can lead to increased protein production.
- Combined Approach: Often, both IHC and ISH are performed to provide a comprehensive evaluation of HER2 status. The results from both tests are then considered to determine if a patient is HER2-positive.
A More Dynamic HER2 Picture
A 2024 review describes advances in HER2-mediated mechanisms and signaling pathways in gastric cancer, while also examining trastuzumab-sensitizing phytochemicals, chemotherapeutics, and nanoparticles as potential adjuncts. A 2026 meta-analysis focuses on discordance between HER2 status in primary gastric tumors and metastatic lesions because such differences may affect treatment decisions. Another 2026 review frames dynamic HER2 reassessment as part of treatment sequencing in advanced gastric cancer.
Where the Strategy Can Fall Short
HER2-directed treatment does not eliminate the possibility of limited benefit or later treatment failure. Differences in tumor biology, testing results, and changes over time can complicate decisions about whether a HER2-targeted approach remains appropriate. These limitations mean that a single test result may not fully capture the clinical situation.
Comparing Tests and Specimens
A comparative study evaluated immunohistochemistry and MS-SRM as methods for identifying gastric cancer patients with HER2 overexpression who may benefit from anti-HER2 treatment. The College of American Pathologists guideline addresses appropriate HER2 testing in advanced gastric and gastroesophageal cancers. A 2026 review emphasizes that evaluation is complicated by heterogeneous, often incomplete HER2 expression and discordant results among biopsies, resections, and metastatic sites.
Empowering Patients Through Knowledge
Understanding HER2 testing and its implications is a crucial step in managing advanced gastric and gastro-oesophageal cancer. By providing clear, accessible information, this article aims to empower patients and their families with the knowledge they need to navigate their treatment journey. Always consult with your healthcare team for personalized guidance and the most up-to-date information regarding your specific situation. With a better understanding of HER2 testing and its role in treatment, patients can actively participate in their care and make informed decisions that lead to the best possible outcomes.
Interpreting HER2 in Context
HER2 testing is best understood as one component of a broader clinical assessment rather than an isolated label. Interpretation may depend on the specimen, assay, tumor heterogeneity, and the patient's treatment history. Clinicians therefore need to connect laboratory findings with the wider disease picture and the available treatment options.
Toward Adaptive Treatment
Future research is likely to examine how HER2 status changes during disease progression and treatment. More refined testing and repeated assessment could help researchers match therapies to changing tumor biology. New targeted agents and combination strategies may expand options, although their clinical value will require careful evaluation.
Progress Alongside Resistance
HER2 was the first molecular biomarker used in gastric cancer, and trastuzumab was the first approved targeted therapy for HER2-positive gastric cancer. Trastuzumab combined with chemotherapy became the standard first-line treatment in advanced settings following the landmark ToGA trial. Resistance to trastuzumab remains a significant challenge, while other biomarkers such as PD-L1 positivity and microsatellite instability can guide immunotherapies including pembrolizumab and nivolumab.
Testing in Everyday Care
The REHEARSAL Study examined real-world treatment patterns, HER2 testing practices, and outcomes among patients in China with HER2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer. It was a multicenter retrospective study conducted across nine sites and registered as NCT06585501. Separately, a 2026 study reported that the clinical implications of HER2-low expression remain uncertain, limiting precise management in the era of antibody-drug conjugates.